Perspective Therapeutics (NYSE:CATX) Given New $16.00 Price Target at Oppenheimer

Perspective Therapeutics (NYSE:CATX) had its target price dropped by analysts at Oppenheimer from $22.00 to $16.00 in a report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target indicates a potential upside of 417.80% from the company’s current price.

A number of other research firms have also issued reports on CATX. UBS Group started coverage on Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Wedbush reiterated an “outperform” rating and issued a $11.00 price target (down from $20.00) on shares of Perspective Therapeutics in a research note on Thursday. Royal Bank of Canada dropped their price objective on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a report on Friday, August 16th. Finally, Truist Financial started coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price for the company. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Perspective Therapeutics has an average rating of “Buy” and an average target price of $19.43.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $3.09 on Friday. The firm has a 50 day moving average of $11.75. Perspective Therapeutics has a fifty-two week low of $2.28 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The firm had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. On average, sell-side analysts expect that Perspective Therapeutics will post -0.86 EPS for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Several large investors have recently modified their holdings of CATX. The Manufacturers Life Insurance Company increased its stake in Perspective Therapeutics by 8.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after buying an additional 1,672 shares during the period. Sykon Capital LLC boosted its holdings in shares of Perspective Therapeutics by 4.7% in the second quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after acquiring an additional 1,717 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Perspective Therapeutics by 5.8% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock worth $783,000 after acquiring an additional 3,211 shares during the period. US Bancorp DE raised its holdings in Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares in the last quarter. Finally, nVerses Capital LLC acquired a new stake in Perspective Therapeutics in the third quarter valued at about $57,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.